References

1. Shankman B. Report of an outbreak of endemic febrile illness, not yet identified, occurring in New York City. N Y State J Med 1946;46:2156–9.
2. Kass EM, Szadniawski WK, Levy H, Leach J, Srinivasan K, Rives C. Rickettsialpox in a New York City hospital, 1980 to 1989. N Engl J Med 1994;331:1612–7.
3. Krusell A, Comer JA, Sexton DJ. Rickettsialpox in North Carolina: a case report. Emerg Infect Dis 2002;8:727–8.
4. Radulovic S, Feng HM, Morovic M, Djelalija B, Popov V, Croquet-Valdes P, et al. Isolation of Rickettsia akari from a patient in a region where Mediterranean spotted fever is endemic. Clin Infect Dis 1996;22:216–20.
5. Comer JA, Tzianabos O, Flynn C, Vlahov D, Childs JE. Serologic evidence of rickettsialpox (Rickettsia akari) infection among intravenous drug users in inner-city Baltimore, Maryland. Am J Trop Med Hyg 1999;60:894–8.
6. Comer JA, Diaz T, Vlahov D, Monterroso E, Childs JE. Evidence of rodent-associated Bartonella and Rickettsia infections among intravenous drug users from Central and East Harlem, New York City. Am J Trop Med Hyg 2001;65:855–60.
7. Sanders S, Di Costanzo D, Leach J, Levy H, Srinivasan K, Zaki SR, et al. Rickettsialpox in a patient with HIV infection. J Am Acad Dermatol 2003;48:286–9.
8. Vural T, Ergan C, Sayin F. Investigation of Rickettsia conorii antibodies in the Antalya area. Infection 1998;26:170–2.
9. Ereneeva M, Balayeva NM, Ignatovich VF, Raoult D. Proteinic and genomic identification of spotted fever group rickettsiae isolated in the former USSR. J Clin Microbiol 1993;10:2625–33.
10. Ereneeva M, Balayeva N, Ignatovich V, Raoult D. Genomic study of Rickettsia akari by pulsed-field gel electrophoresis. J Clin Microbiol 1995;33:3022–4.

Address for correspondence: Suzana Radulovic, University of Maryland, School of Medicine, Department of Microbiology and Immunology, 655 West Baltimore Street, Baltimore, MD 21201, USA; fax: 410 706 4721; email: sradu001@umaryland.edu

Human Granulocytic Ehrlichiosis in Estonia

To the Editor: We report a case of a 24-year-old woman living in a rural area of Estonia who had weakness, chills, and diarrhea on May 10, 2002. On day 5 of the illness, she was admitted to the Department of Infectious Diseases, University of Tartu, with high fever (38.5°C) and muscle pains throughout her body. Examination showed mild jaundice, painful and enlarged liver, and inability to move. Throat was erythematous, and enlarged lymph nodes were palpable on the neck.

Laboratory findings included the following: leukopenia 2.04x10^9/L; erythrocytes 4.08x10^{12}/L; hemoglobin 130 g/L; thrombocytopenia 36x10^{12}/L; eosinophils 0%; basophils 1.0%; monocytes 7.5%; lymphocytes 38.0%; neutrophils 51.0%; reactive lymphocytes 2.0%; plasma cells 0.5%; C-reactive protein 38 mg/L (normal <5 mg/L); bilirubin 95 µmol/L (normal <17 µmol/L); aspartate aminotransferase 121 U/L (normal <31 U/L); alanine aminotransferase 108 UL (normal <31 U/L); and alkaline phosphatase 200 U/L (normal 35–104 U/L). Ehrlichiosis was suspected by clinical symptoms and leukopenia, thrombocytopenia, and elevated transaminases.

Human granulocytic ehrlichiosis (HGE) is an emerging tick-borne disease described for the first time in 1994 in the United States (1). The first European case of HGE was reported in Slovenia in 1996 (2). Infection with Ehrlichia phagocytophila, the agent of HGE, occurs in areas endemic for Borrelia burgdorferi (3). In Estonia, Lyme borreliosis is frequently diagnosed in humans but the occurrence of ehrlichiosis has not been established for this region, despite our having found some seropositive results in Lyme borreliosis patients (4).

This case of ehrlichiosis is the first diagnosed in Estonia. The initial diagnosis was based on a typical clinical spectrum of symptoms and clinical laboratory findings, which are relatively nonspecific, making the diagnosis problematic (5). Polymerase chain reaction results for Ehrlichia were negative, and we did not find morula in the blood smear. Indirect immunofluorescence assay (IFA, MRL Diagnostics, Cypress, CA) was used as a confirmatory serologic test. However, results of this assay are often negative during the initial phase...
of the disease (5,6). On day 7 of illness, the serologic results for immunoglobulin (Ig) M type antibodies to *Ehrlichia* were positive (1:20) and negative for IgG. The diagnosis of ehrlichiosis was established, and therapy with doxycycline was started. After 4 days, the patient became afebrile, and on day 6 she left for home. One month later, the titers of both types of antibodies to *Ehrlichia* were increased: IgM titer was 1:160 and IgG titer was 1:128; 6 months later, IgM antibodies were negative, and the IgG titer remained unchanged.

Our patient had a typical spectrum of clinical and laboratory changes to *Ehrlichia*, but not very specific findings of infection with *E. phagocytophila*. The results of IFA, i.e., IgM antibodies in the beginning of the disease and increasing titer of IgG antibodies during the course of the disease, confirmed the diagnosis. Granulocytic ehrlichiosis should be considered in patients with tick-associated fever.

**Tiina Prükk,* Kylli ki Ainsalu,† Ene Laja,‡ and Ada Aigro‡**

*University of Tartu, Tartu, Estonia; †Internal Medicine Clinic of Tartu University, Tartu, Estonia; and ‡United Laboratories of Tartu University Clinics, Tartu, Estonia*

**References**

1. Bakken JS, Dumler S, Chen SM, VanEtta LL, Eckman MR, Walker DH. Human granulocytic ehrlichiosis in the United States: a new species emerging? JAMA 1994;272:212–8.
2. Petrovec M, Lotric-Furlan S, Avsic-Zupanc T, Strle F, Brouqui P, Roux V, et al. Human disease in Europe caused by a granulocytic *Ehrlichia* species. J Clin Microbiol 1997;35:1556–9.
3. Bjöersdorff A, Wittebo B, Berglund I, Massung RF, Eliasson I. Human granulocytic ehrlichiosis as a common cause of tick-associated fever in Southeast Sweden: report from a prospective clinical study. Scand J Infect Dis 2002;34:187–91.
4. Prükk T, Nilsson I, Bjöersdorff A, Wadström T. Seroprevalence of ehrlichiosis in south-Estonia. Budapest: First Congress of the European Society for Emerging Infections; 1998.
5. Lotric-Furlan S, Avsic-Zupanc T, Petrovec M, Nicholson WL, Sumner JW, Childs JE, et al. Clinical and serological follow-up of patients with human granulocytic ehrlichiosis in Slovenia. Clin Diagn Lab Immunol 2001;8:899–903.
6. Olano JP, Walker DH. Human ehrlichioses: diagnostic challenges and therapeutic recommendations. Infect Med 2002;19:318–25.

Address for correspondence: T. Prükk, Department of Infectious Diseases, University of Tartu, Lina 6,51004, Tartu, Estonia; fax: 372 7 374232; email: tiinap@cut.ee